Intervention not reported
Mean total blood loss (mL): tranexamic acid vs placebo · children undergoing surgery for scoliosis
1 finding from 1 review
Intervention not reported
Number of participants receiving blood transfusion: aprotinin vs placebo · children undergoing surgery for scoliosis
It is very uncertain whether the intervention changes number of participants receiving blood transfusion: aprotinin vs… (very low certainty).
1 finding from 1 review
Intervention not reported
Number of participants receiving blood transfusion: tranexamic acid vs placebo · children undergoing surgery for scoliosis
It is very uncertain whether the intervention changes number of participants receiving blood transfusion: tranexamic acid… (very low certainty).
1 finding from 1 review
Overall survival (Death) · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines showed no clear difference in overall survival (Death) compared with single agent IRI (low certainty).
1 finding from 1 review
Progression‐free survival (PSF) · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines probably leads to lower progression‐free survival (Disease progression) compared with single agent IRI (moderate certainty).
1 finding from 1 review
Grade 3/4 diarrhea · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines probably leads to lower grade 3/4 diarrhea compared with single agent IRI (moderate certainty).
1 finding from 1 review
Grade 3/4 nausea · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines showed no clear difference in grade 3/4 nausea compared with single agent IRI (low certainty).
1 finding from 1 review
Induction of remission (CDAI <150), therapeutic response (VHI decrease >=25%) or clinical improvement · patients with Induction of remission or response in Crohn's disease
Sulfasalazine showed no clear difference in induction of remission (CDAI <150), therapeutic response (VHI… compared with placebo (low certainty).
1 finding from 1 review
Clinical remission or improvement · patients with Induction of remission or response in Crohn's disease
It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission or clinical improvement ‐ Asacol (3.2 g/day) compared with placebo (very low certainty).
2 findings from 1 review
Induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2 g/day) · patients with Induction of remission or response in Crohn's disease
It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2… compared with placebo (very low certainty).
1 finding from 1 review
Induction of remission (CDAI < or =150 with or without decrease of at least 60 points) · patients with Induction of remission or response in Crohn's disease
Delayed‐release mesalamine (3 ‐ 4.5 g/day) showed no clear difference in induction of remission (CDAI < or =150 with or without decrease of… compared with corticosteroids (moderate certainty).
5 findings from 1 review
RR 1.04 [0.79, 1.36]
3 studies · 178 participants
Moderate
RR 0.95 [0.49, 1.85]
1 study · 50 participants
Low
RR 1 [0.61, 1.64]
1 study · 50 participants
Moderate
Show 2 more findings
Induction of clinical remission (CDAI < or = 150) · patients with Induction of remission or response in Crohn's disease
Mesalamine (4 ‐ 4.5 g/day) may leads to lower induction of remission (CDAI < or = 150) ‐ Pentasa (4 g/day) compared with budesonide (low certainty).
2 findings from 1 review
Clinical remission or improvement · patients with Induction of remission or response in Crohn's disease
It is very uncertain whether mesalamine changes induction of remission (CDAI < 150) or clinical improvement ‐… compared with sulfasalazine (alone or (very low certainty).
2 findings from 1 review
Remission · patients with Induction of remission or response in Crohn's disease
Sulfasalazine showed no clear difference in induction of remission (CDAI <150) (Random Effects Model) compared with placebo (moderate certainty).
1 finding from 1 review
CDAI <150 at 24 weeks · patients with Induction of remission or response in Crohn's disease
Sulfasalazine probably leads to lower induction of remission (CDAI <150) compared with corticosteroids (moderate certainty).
1 finding from 1 review
Remission · patients with Induction of remission or response in Crohn's disease
Sulfasalazine probably leads to lower induction of remission compared with sulfasalazine and corticosteroids (moderate certainty).
1 finding from 1 review
Decrease in CDAI >=50, HBI >=2 or improvement/remission (as defined by Tvede et al) · patients with Induction of remission or response in Crohn's disease
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in decrease in CDAI >=50, HBI >=2 or improvement/remission (as defined… compared with placebo (low certainty).
1 finding from 1 review
Induction of remission (CDAI <=150 + decrease of >=50 or as defined by Tvede et al) · patients with Induction of remission or response in Crohn's disease
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in induction of remission (CDAI <=150 + decrease of >=50 or as defined… compared with placebo (low certainty).
1 finding from 1 review
Mean change in baseline CDAI (Random effects model) · patients with Induction of remission or response in Crohn's disease
1 finding from 1 review
Mean change in baseline CDAI (Fixed effects model) · patients with Induction of remission or response in Crohn's disease
1 finding from 1 review